This is yet another I-O clinical collaboration in which no cash is changing hands.
I think another important point is that TLOG actually has to fund the Phase 1 study. Makes this collaboration even less impressive to me for TLOG (would be more impressed if MRK paid a nice up-front or at least agreed to fund the next trial).